Hyperuricemia
Conditions
Brief summary
Uric acid, a metabolic byproduct of purine degradation in humans, is a known risk factor for conditions such as gout and type 2 diabetes. Research has shown that supplementation with quercetin can significantly reduce plasma uric acid levels in individuals with mild hyperuricemia, potentially mitigating these associated risks.
Detailed description
Uric acid, a metabolic byproduct of purine degradation in humans, is a significant risk factor for the development of gout and type 2 diabetes. Supplementation with quercetin, a flavonol not naturally produced by the human body, has been shown to significantly reduce plasma uric acid levels in individuals with mild hyperuricemia. This effect is primarily achieved through the inhibition of xanthine oxidoreductase, an enzyme crucial to uric acid production. Quercetin is the most abundant polyphenol found in fruits and vegetables and is widely used as a dietary supplement to boost the immune system and promote overall health. It is characterized by three key properties: antioxidant, anti-inflammatory, and immunomodulatory. These combined actions make quercetin a promising candidate for supporting various health conditions where oxidative stress, inflammation, and immune function play a role, including cardiovascular health, healthy aging, bone and joint health, sports and physical activity, gut health, and respiratory well-being. The above-described properties of quercetin prompted investigators to explore its potential uricosuric therapeutic effect in two clinical studies. The first study will assess this effect in a retrospective cohort of COVID-19 patients who received quercetin as a supplemental therapy. In the second study, its potential uricosuric therapeutic effect will be assessed in a randomized controlled prospective clinical trial involving patients with mild to moderate hyperuricemia.
Interventions
DIETARY_SUPPLEMENTQuercetin
200 mg supplemental Quercefit®
COMBINATION_PRODUCTBerberol K®
Berberine Phytosome® 730 mg \+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract
Sponsors
University of Urbino Carlo Bo
Liaquat University of Medical & Health Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged between 18 and 75 years. * Diagnosed with obesity. * Diagnosed with hypercholesterolemia. * With or without moderate hyperuricemia (serum uric acid ≥ 8 mg/dL). * No restrictions on BMI, alcohol consumption, or smoking habits.
Exclusion criteria
* Current use of uric acid-lowering medications (e.g., allopurinol, febuxostat). * Diagnosed with oncological diseases. * Diagnosed with neurological diseases. * Diagnosed with inflammatory bowel diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect on circulatory uric acid | 90 days | Change in plasma uric acid level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect on lipids | 90 days | Change in plasma cholesterol level |
| Effect on glycemia | 90 days | Change in plasma glucose level |
| Effect on body internal organs muscles | 90 days | Change in the Creatine Phosphokinase (CPK) levels |
| Effect on liver function | 90 days | Change in the Alanine Aminotransferase levels |
| Supplement safety and tolerability | 90 days | Number of patients reporting possible side effects |
Countries
Italy
Outcome results
None listed